JP2023504560A - ｃ－Ｋｉｔ変異を発現する細胞およびその使用 - Google Patents

ｃ－Ｋｉｔ変異を発現する細胞およびその使用 Download PDF

Info

Publication number
JP2023504560A
JP2023504560A JP2022533605A JP2022533605A JP2023504560A JP 2023504560 A JP2023504560 A JP 2023504560A JP 2022533605 A JP2022533605 A JP 2022533605A JP 2022533605 A JP2022533605 A JP 2022533605A JP 2023504560 A JP2023504560 A JP 2023504560A
Authority
JP
Japan
Prior art keywords
cells
cell
antigen
car
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533605A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023504560A5 (https=
Inventor
プラサッド エス． アドゥスミリ，
ユチュアン ション，
Original Assignee
メモリアル スローン ケタリング キャンサー センター
スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ
メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メモリアル スローン ケタリング キャンサー センター, スローン － ケタリング・インスティテュート・フォー・キャンサー・リサーチ, メモリアル ホスピタル フォー キャンサー アンド アライド ディジージズ filed Critical メモリアル スローン ケタリング キャンサー センター
Publication of JP2023504560A publication Critical patent/JP2023504560A/ja
Publication of JP2023504560A5 publication Critical patent/JP2023504560A5/ja
Priority to JP2025165386A priority Critical patent/JP2026017553A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022533605A 2019-12-03 2020-12-03 ｃ－Ｋｉｔ変異を発現する細胞およびその使用 Pending JP2023504560A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025165386A JP2026017553A (ja) 2019-12-03 2025-10-01 ｃ－Ｋｉｔ変異を発現する細胞およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943032P 2019-12-03 2019-12-03
US62/943,032 2019-12-03
PCT/US2020/062992 WO2021113432A1 (en) 2019-12-03 2020-12-03 Cells expressing c-kit mutations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025165386A Division JP2026017553A (ja) 2019-12-03 2025-10-01 ｃ－Ｋｉｔ変異を発現する細胞およびその使用

Publications (2)

Publication Number Publication Date
JP2023504560A true JP2023504560A (ja) 2023-02-03
JP2023504560A5 JP2023504560A5 (https=) 2023-12-04

Family

ID=76222653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022533605A Pending JP2023504560A (ja) 2019-12-03 2020-12-03 ｃ－Ｋｉｔ変異を発現する細胞およびその使用
JP2025165386A Pending JP2026017553A (ja) 2019-12-03 2025-10-01 ｃ－Ｋｉｔ変異を発現する細胞およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025165386A Pending JP2026017553A (ja) 2019-12-03 2025-10-01 ｃ－Ｋｉｔ変異を発現する細胞およびその使用

Country Status (8)

Country Link
US (1) US20230051518A1 (https=)
EP (1) EP4069730A4 (https=)
JP (2) JP2023504560A (https=)
CN (1) CN115210254A (https=)
AU (1) AU2020395175A1 (https=)
CA (1) CA3163872A1 (https=)
IL (1) IL293598A (https=)
WO (1) WO2021113432A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
EP4532693A1 (en) * 2022-05-25 2025-04-09 Albert Einstein College of Medicine Methods for producing red blood cells
WO2023248126A1 (en) * 2022-06-20 2023-12-28 Crispr Therapeutics Ag Chimeric antigen receptor specific to cd117
WO2025117266A2 (en) * 2023-11-27 2025-06-05 Albert Einstein College Of Medicine Method of producing self-renewing erythroid cells from human progenitor cells
CN118725143B (zh) * 2024-07-15 2025-12-02 上海交通大学医学院附属瑞金医院 靶向kit d816v突变衍生抗原的tcr及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1427422A1 (en) * 2001-09-20 2004-06-16 AB Science Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
EP2892930B1 (en) * 2012-09-07 2019-08-14 University Of Miami Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof
US10835525B2 (en) * 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
EP4166148B1 (en) * 2014-06-06 2026-02-18 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US20190309307A1 (en) * 2016-09-14 2019-10-10 Benitec Biopharma Limited REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF
CN109251183A (zh) * 2017-07-13 2019-01-22 广东东阳光药业有限公司 取代脲衍生物的晶型及其在药物中的应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CEM AKIN ET AL.: ""Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutat", EXPERIMENTAL HEMATOLOGY, vol. 28, no. 2, JPN6024043909, February 2000 (2000-02-01), pages 140 - 147, ISSN: 0005805933 *
HONGYO T ET AL.: ""Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan."", CANCER RESEARCH, vol. 60, no. 9, JPN6024043907, 1 May 2000 (2000-05-01), pages 2345 - 7, ISSN: 0005805935 *
MARCIA L. TAYLOR ET AL.: ""The Kit-activating mutation D816V enhances stem cell factor-dependent chemotaxis"", BLOOD, vol. 98, no. 4, JPN6024043906, 15 August 2001 (2001-08-15), pages 1195 - 1199, ISSN: 0005805936 *
MINORU HASEGAWA: ""B lymphocyte,自己免疫性疾患の病態形成に関わる細胞・分子と臨床応用 Ｂ細胞"", JAPANESE JOURNAL OF CLINICAL IMMUNOLOGY, vol. 28, no. 5, JPN6024043908, 2005, pages 300 - 308, ISSN: 0005805934 *
T FURITSU ET AL.: ""Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cel", JOURNAL OF CLINICAL INVESTIGATION, vol. 92, no. 4, JPN6024043905, 1 October 1993 (1993-10-01), pages 1736 - 1744, ISSN: 0005805937 *

Also Published As

Publication number Publication date
CN115210254A (zh) 2022-10-18
US20230051518A1 (en) 2023-02-16
IL293598A (en) 2022-08-01
EP4069730A4 (en) 2023-11-01
WO2021113432A1 (en) 2021-06-10
CA3163872A1 (en) 2021-06-10
AU2020395175A1 (en) 2022-07-07
EP4069730A1 (en) 2022-10-12
JP2026017553A (ja) 2026-02-04

Similar Documents

Publication Publication Date Title
JP2025172139A (ja) 非ｈｌａ制限ｔ細胞受容体およびその使用
JP7676358B2 (ja) 免疫療法のための融合ポリペプチド
CN113166226B (zh) 表达显性负性fas的免疫应答细胞及其用途
US20230051518A1 (en) Cells expressing c-kit mutations and uses thereof
JP7668261B2 (ja) 改良された免疫療法のための細胞およびその使用
CN111655270A (zh) 分泌il-36的免疫应答细胞及其用途
US20230051064A1 (en) Chimeric antigen receptors with cd28 mutations and use thereof
JP7776414B2 (ja) Ｃｄ３７１を標的にする抗原認識受容体およびその使用
EP3710470A1 (en) Il-33 secreting immunoresponsive cells and uses thereof
CN120641436A (zh) 基于内含肽的分选系统和模块化嵌合多肽
JP2025169261A (ja) 新規ドミナントネガティブｆａｓポリペプチド、それらを含む細胞、及びそれらの使用
CA3228546A1 (en) Antigen recognizing receptors targeting cd33 and uses thereof
WO2019178207A1 (en) Phosphatidylserine targeting agents and uses thereof for adoptive t-cell therapies
HK40040021A (en) Enhanced chimeric antigen receptors and uses thereof
BR122024009352A2 (pt) Receptor de antígeno quimérico (car), célula imunorresponsiva isolada e seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir uma célula imunorresponsiva que se liga ao antígeno de maturação de célula b (bcma), composição farmacêutica e kit para tratar uma neoplasia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231124

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250311

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20251119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260424